Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

31.49 -0.53 (-1.66%)

Streaming Delayed Price Updated: 11:59 AM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Teva Pharma is the way to play the re-rise of generic drugs

November 28, 2023

Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth

Via MarketBeat

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

2 overlooked stocks that crushed earnings but traded lower

November 20, 2023

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

Via MarketBeat

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

November 17, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

November 13, 2023

From Royalty Pharma plc

Via GlobeNewswire

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

November 13, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

November 08, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

November 07, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting

November 02, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

November 01, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program

October 25, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

October 17, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023

October 06, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

October 04, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Changes to Executive Management Team

September 28, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

September 06, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

September 06, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Settles Price Fixing Charges With U.S. DOJ

August 21, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Reports Second Quarter 2023 Financial Results

August 02, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

July 27, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

July 24, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

July 24, 2023

From Alvotech

Via GlobeNewswire

Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023

July 05, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

June 30, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients

June 15, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims

June 12, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

June 12, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

June 12, 2023

From Alvotech

Via GlobeNewswire

Teva Concludes Nationwide Opioids Settlement Agreement

June 08, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

June 06, 2023

From Phil Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.